The NHS under-invests at its peril
pharmafile | February 1, 2008 | Feature | |Â Â NHS, healthcare, investmentÂ
Related Content

PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres
PlaqueTec’s BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist …

Envirogen secures place on NHS Scotland reverse osmosis framework
Envirogen has been appointed to Lot 6, covering reverse osmosis (RO), of the national Decontamination …

AbbVie expands Oxford R&D facility with new £120m UK research commitment
AbbVie has expanded its Oxford research and development (R&D) facility with a new 12,000 sq …





